---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-117765"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:31:08.857916+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reprices stock options to $3.91; original exercise price applies if exercised before Premium End Date

## Summary
- Board approved repricing of all outstanding options to $3.91 per share (closing price on March 19, 2026).
- Repriced options subject to original exercise price if exercised before Premium End Date (Sept 19, 2027, change in control, or death/disability).
- Named executive officers hold 1,106,764 total Eligible Options with original exercise prices ranging from $6.60 to $17.88.
- CEO Eric Easom holds 742,649 repriced options; CFO Lucy Day holds 221,965; CLO/COO Joshua Eizen holds 142,150.

## SEC filing metadata
- accession: 0001193125-26-117765
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312526117765/0001193125-26-117765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312526117765/d107794d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-117765
- JSON: https://secwatch.observer/filing/0001193125-26-117765.json
- Plain text: https://secwatch.observer/filing/0001193125-26-117765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.